NASDAQ$OABI
OmniAb Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported financial results and business highlights for Q4 2023.
OmniAb reported a decrease in revenue for the fourth quarter of 2023, primarily due to the recognition of a $25.0 million milestone payment in the prior-year period and lower service revenue. The company signed 10 new licenses in 2023, including three in the fourth quarter.
- Revenue for the fourth quarter of 2023 was $4.8 million, compared to $35.3 million for the same period in 2022.
- Net loss for the fourth quarter of 2023 was $14.1 million, or $0.14 per diluted share, compared to net income of $6.8 million, or $0.07 per share, for the same period in 2022.
- Signed 10 new licenses in 2023, including three in the fourth quarter, with Enable Life Sciences, Mirador Therapeutics, and a global pharma company.
- Launched two new technologies during 2023 including OmniDeep™ and, during the fourth quarter, OmnidAb™.
Headline financials
Revenue & EPS history
OmniAb · Revenue · Quarterly
$4.82M
Revenue by segment
OmniAb · $5.48M total across 3 segments · Q3 2023
- Service Revenue$3.02M—55.1%
- License and Milestone$2.01M—36.7%
- Royalty Revenue$451K—8.2%
Forward guidance
OmniAb expects operating expense in 2024 to be approximately the same as in 2023, and its cash use in 2024 to be relatively similar to its cash used in 2023, excluding the $35 million TECVAYLI milestone payment received in 2023.
Tailwinds
- Operating expense in 2024 expected to be approximately the same as in 2023.
- Cash use in 2024 expected to be relatively similar to cash used in 2023, excluding the $35 million TECVAYLI milestone payment.
- Cash use in 2025 expected to be substantially lower than in 2024.
- Current cash balance and cash from operations are expected to provide sufficient capital to fund operations for the foreseeable future.
- Now staffed and resourced to leverage the future growth of the business.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2023
-2.1%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+4.1%
Avg return
30 days after
39%
7 / 18 earnings
Positive
+9.9%
Q4 2025
Best reaction
-20.4%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.1% | +29.4% | +72.7% | |
| Q4 2025 | +9.9% | +9.9% | -14.9% | |
| Q3 2025 | -4.1% | +0.7% | +31.8% | |
| Q1 2025 | -7.2% | -3.2% | -4.5% | |
| Q4 2024 | -20.4% | -20.4% | -43.9% | |
| Q3 2024 | -11.5% | -15.7% | -13.0% | |
| Q2 2024 | +4.4% | +4.9% | -2.2% | |
| Q1 2024 | +3.1% | -0.9% | +2.2% | |
| Q4 2023 | -2.5% | +0.8% | -11.4% | |
| Q3 2023 | -6.8% | +3.5% | +7.3% | |
| Q2 2023 | -5.7% | -3.8% | -10.4% | |
| Q1 2023 | +6.1% | +16.1% | +37.3% | |
| Q4 2022 | +9.5% | +10.1% | +3.6% | |
| Q3 2022 | -15.5% | -4.1% | +19.3% | |
| Q2 2022 | +0.2% | +0.1% | +0.3% | |
| Q1 2022 | -0.0% | +0.0% | +0.1% | |
| Q4 2021 | -0.0% | -0.1% | -0.1% | |
| Q3 2021 | +0.0% | +0.0% | -0.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro